Published 4 days ago • loading... • Updated 2 days ago

Hims & Hers to offer at-home blood draws and lab testing with new acquisition

Hims & Hers Health has acquired Trybe Labs, enabling at-home blood draws and lab testing for its users.
The acquisition aims to provide competition to services like Labcorp and Quest Diagnostics, according to Hims & Hers.
Dr. Patrick Carroll stated that richer data from tests will enhance clinical decisions for patients.
Hims & Hers plans to roll out the new testing services within the next year.

Insights by Ground AI

Does this summary seem wrong?

11 Articles

All

Left

Center

Right

Fast Company

Hims & Hers stock surges 23%: Telehealth company announces expansion into blood testing weeks after Super Bowl buzz

Amid a month of skyrocketing stock prices and unprecedented social media buzz, Hims & Hers is expanding its territory into at-home blood testing and diagnostics. Hims has acquired at-home lab testing facility Trybe Labs, the telehealth company said Wednesday. Using at-home blood draws, Hims will now offer over 70 at-home diagnostics tests, ranging from heart health to certain cancer detection tests. All these can be arranged through the app, wit…

3 days ago

Read Full Article

sherwood.news

Hims & Hers to provide at-home blood testing with new acquisition

The company says it will use blood-testing data to help develop an AI-powered system that will provide “personalized care.”...

3 days ago

Read Full Article

CNBC

Hims & Hers to offer at-home blood draws and lab testing with new acquisition

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

3 days ago·United States

Read Full Article

Seeking Alpha

Hims & Hers stock in focus on Trybe Labs buyout (HIMS:NYSE)

Hims & Hers (NYSE:HIMS) stock in focus as the company expands telehealth services with the acquisition of at-home lab testing facility, Trybe Labs. Read more here.

3 days ago·United States

Read Full Article

Quartz

Hims & Hers is getting into the at-home blood testing business

After having massive success with off-brand weight-loss drugs, the millennial-focused telehealth company Hims & Hers (HIMS) is now expanding its offerings to include at-home blood tests.Read more...

4 days ago·United States

Read Full Article

braziljournal.com

Hims & Hers took the friction out of the traditional medical market — and its stock exploded

The 'miraculous' Ozempic doesn't fit every pocket. In the USA, those who do not have at least partial health insurance coverage spend an average of US$ 936 a month on the drug. The telemedicine startup Hims & Hers Health saw an opportunity to boost its business, based on subscription plans for medical treatments. Semaglutide, the active ingredient in Ozempic and Wegovy, is still under patent protection, which belongs to the Danish company Novo N…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year